


PRODUCT INFORMATION



AM630

Item No. 10006974

CAS Registry No.: 164178-33-0
Formal Name: [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone
Synonym: 6-Iodopravadoline
MF: C₂₃H₂₅IN₂O₃
FW: 504.4
Purity: ≥98%
UV/Vis.: λ_{max}: 229, 283 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AM630 is supplied as a crystalline solid. A stock solution may be made by dissolving the AM630 in the solvent of choice. AM630 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of AM630 in these solvents is approximately 3 and 10 mg/ml, respectively.

AM630 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AM630 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. AM630 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

AM630 binds selectively to cannabinoid 2 (CB₂) over CB₁ receptors with K_i values of 31.2 and 5,152 nM, respectively.¹ AM630 acts as an inverse agonist at CB₂ receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB₁ receptors.¹⁻³ It decreases proliferation and induces arrest of the cell cycle at the G₂/M phase in renal cell carcinoma cells.⁴

References

1. Ross, R.A., Brockie, H.C., Stevenson, L.A., *et al.* Agonist-inverse agonist characterization at CB₁ and CB₂ cannabinoid receptors of L759633, L759656 and AM630. *Br. J. Pharmacol.* **126**(3), 665-672 (1999).
2. Malan, T.P., Jr., Ibrahim, M.M., Deng, H., *et al.* CB₂ cannabinoid receptor-mediated peripheral antinociception. *Pain* **93**(3), 239-245 (2001).
3. Bisogno, T., Ortar, G., Petrosino, S., *et al.* Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity *in vivo*. *Biochim. Biophys. Acta* **1791**(1), 53-60 (2009).
4. Wang, J., Xu, Y., Zhu, L., *et al.* Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. *J. Cancer Res. Clin. Oncol.* (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM